Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P-SELECT: weekly paclitaxel + ramucirumab versus weekly nab-paclitaxel + ramucirumab in advanced gastric or esophagogastric junction adenocarcinoma with peritoneal dissemination
jRCTs031180022Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Oct 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of paclitaxel and ramucirumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Overall survival. Started Oct 2018; status: completed.
02
Drugs
paclitaxelramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCTs031180022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180022.